Login

Financial Snapshot

Revenue
TTM
$1.180M
Gross Margin
TTM
80.68%
Net Income
TTM
-$2.026M
Current Assets
2025 Q4
$23.68M
Current Liabilities
2025 Q4
$12.12M
Current Ratio
2025 Q4
195.34%
Total Assets
2025 Q4
Total Liabilities
2025 Q4
Book Value
2025 Q4
$23.35M
Cash
2025 Q4
$3.250M
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$5.818M

Stock Price

Loading...
Market Cap: $41.936 Million

About BioLine RX Ltd

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. The company is headquartered in Modiin, Central(Hamerkaz) and currently employs 24 full-time employees. The company went IPO on 2007-01-30. The firm is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The firm is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Industry: Pharmaceutical Preparations Peers: Enlivex Ltd Collplant Biotechnologies Ltd Gamida Cell Ltd. Kamada Ltd Urogen Pharma Ltd

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support